Cochrane · systematic review · CD003115

Oral or transdermal opioids for osteoarthritis of the knee or hip

da Costa, BR, Nüesch, E, Kasteler, R, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library

Musculoskeletal2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 2 · 33.3%High 3 · 50%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip

Population: participants with osteoarthritis of the knee or hip
6 questions
OutcomeEffectEvidenceStatus / GRADE
Pain intensity Various pain scales. (median
Oral or transdermal opioids vs placebo
no estimate extracted22 studies · 8275 participantsHigh
Function Various validated function scales. (median
Oral or transdermal opioids vs placebo
no estimate extracted12 studies · 3553 participantsHigh
Number of participants experiencing any adverse event (median
Oral or transdermal opioids vs placebo
RR 1.49 [1.35, 1.63]9 studies · 4898 participantsModerate
Downgraded: risk of bias
Number of participants who withdrew because of adverse events (median
Oral or transdermal opioids vs placebo
RR 3.76 [2.93, 4.82]19 studies · 7712 participantsHigh
Number of participants experiencing any serious adverse event (median
Oral or transdermal opioids vs placebo
RR 3.35 [0.83, 13.56]3 studies · 681 participantsLow
Downgraded: risk of bias
Withdrawal symptoms (median
Oral or transdermal opioids vs placebo
OR 2.67 [2.02, 3.77]3 studies · 1151 participantsModerate
Downgraded: risk of bias